0
Cardiovascular Disease |

Is Use of Anticoagulant/Antiplatelet Agent for Atrial Fibrillation in Outpatient Guided by Risk Stratification? A Study in New Anticoagulant Agent Prevailing Day

Nobuyki Anzai*, MHA; Hiroko Anzai, MD; Rieko Mitobe, MD; Makiko Anzai, MD; Kei Goto, MN
Author and Funding Information

Anzai-Furuya Clinic, Oyam, Japan


Chest. 2012;142(4_MeetingAbstracts):108A. doi:10.1378/chest.1382004
Text Size: A A A
Published online

Abstract

SESSION TYPE: Arrhythmias Posters

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: Little is known about whethher the recent use of anticoagulant/antiplatelet agent for atrial fibrillation(AF) in outpatient is guided by risk stratification in new anticoagulant prevailing day.

METHODS: 172 patients with AF, who was followed at our clinic between Jan 2011 and Dec 2011, were investigated on recent anticoagulant/antiplaelet use stratified by CHADS2 score. The decision for anticoagulant/ antiplatelet use was made by the attending physicians at outpatient(2 cardiology, 1pulmonology, 1general). No intervention to guide anticoagulant orantiplaelet therapy was made.

RESULTS: The age was 76.4(SD 22.5%), 29.0% female, 23.3% of patients were paroxymal AF, 76.6% were persistent/permanent AF. The prevalence of clinical conditions and associated comorbidities in CHADS"2 score were as follows: left ventricular dysfunction(27.2%), left atrial enlargement(27.7%), ischemic heart disease(7.5%), congenital heart disease(3.5%),cardiomyopathy(4.0%), hypertension(61.3%), age≧75(48.0%), diabetes(21.4%),,stoke/transient ischemic attack(11.6%). The mean CHADS score was 2.2(SD 1.1). The percentage of patients with CHADS2 score from 0 to 6 were 4.7%, 20.3%, 35.4%, 23.8%, 7.3%, 4.3% and 1.7%,respectively. The anticoagulat use was 67.4%, antiplatelet 9.2% and no use of both 23,3%. The percentage of patients on anticoagulant use with CHADS2 score from 0 to 6 were 37, 5%, 65,7%, 65.6%, 82.9%,68.8%, 50.0% and 33.3%, respectively.The proportion of antiplatelet use by increasing CHADS2 score were 5.9%, 29.4%, 35.3%, 17.6%, 5.9%,5.9% and nonetimable,respectively.

CONCLUSIONS: The anticoagulant agent was used on low risk AF patients, whereas thier use in patients with high risk was low or not used.

CLINICAL IMPLICATIONS: The results is useful to improve appropriate anticoagulant use and further patient education.

DISCLOSURE: The following authors have nothing to disclose: Nobuyki Anzai, Hiroko Anzai, Rieko Mitobe, Makiko Anzai, Kei Goto

No Product/Research Disclosure Information

Anzai-Furuya Clinic, Oyam, Japan

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543